NOVAVAX INC Finance Lease, Liability, Current
NOVAVAX INC (NVAX) had Finance Lease, Liability, Current of $4.11 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:FinanceLeaseLiabilityCurrent · last filed 2026-08-06
- 2026-06-30: Finance Lease, Liability, Current $4.11M.
- 2026-03-31: Finance Lease, Liability, Current $2.11M.
- 2025-12-31: Finance Lease, Liability, Current $2.51M.
- 2025-09-30: Finance Lease, Liability, Current $5.04M.
| Period end | Finance Lease, Liability, Current |
|---|---|
| 2026-06-30 | $4.11M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $2.11M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $2.51M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $5.04M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $5.55M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $5.48M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $7.01M 10-K · filed 2026-02-26 |
| 2024-09-30 | $9.68M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $9.43M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $6.29M 10-Q · filed 2024-05-10 |
| 2023-12-31 | $5.14M 10-K · filed 2025-02-27 |
| 2023-09-30 | $1.33M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $953.00K 10-Q · filed 2023-08-08 |
| 2023-03-31 | $1.21M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $27.20M 10-K · filed 2024-02-28 |
| 2022-09-30 | $82.09M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $124.26M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $116.68M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $130.53M 10-K · filed 2023-02-28 |
| 2021-09-30 | $103.99M 10-Q · filed 2021-11-05 |
| 2021-06-30 | $98.38M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $121.14M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $105.86M 10-K · filed 2022-03-01 |
| 2020-09-30 | $55.86M 10-Q · filed 2020-11-10 |
| 2019-12-31 | $0.00 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |